KRAS and non-small cell lung carcinoma: To identify differences in kinase signaling in KRAS-mutant NSCLC cells with or without LKB1, we performed mass spectrometry-based global phosphoproteome profiling39 of isogenic H2030 (EV, LKB1 and LKB1-kd) and H358 (KO GFP, KO LKB1) cells before and after treatment with trametinib (Fig. 3A).